InMode Ltd. (INMD) stock
Close on Nov 12, 2026Market cap $835.70MP/E 9.2Yield –
InMode Ltd. saw revenue fall 6.2% to $370.50M over fiscal 2025. Operating income fell 24.1% to $85.39M, moving the operating margin from 28.5% to 23.0%. Free cash flow was $84.29M, down 36.1% from a year earlier. At the latest close the market valued the company at $835.70M, 9.2 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $835.70M
- P/E ratio
- 9.2
- Price to sales
- 2.26
- Price to book
- 1.22
- Dividend yield
- –
- Free cash flow yield
- 10.09%
Fundamentals
- Revenue
- $370.50M
- EPS, diluted
- $1.43
- Free cash flow
- $84.29M
Trading
- Previous close
- $13.73
- Open
- $13.42
- Day's range
- $13.08 – $13.51
- Volume
- 796,474
- Average volume (20 days)
- 615,474
- Beta (5 years)
- 1.43
- 52-week range
- $12.72 – $16.67
- RSI (14 days)
- 40.3
- Volatility (1 year)
- 31.3%
- Relative volume
- 1.50×
- WACC
- 12.0%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | INMD | S&P 500 | Difference | INMD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.8% | -2.7% | −5.1 pts | ||
| 3 months | -13.4% | -1.7% | −11.6 pts | ||
| Year to date | -10.2% | +11.9% | −22.1 pts | ||
| 1 year | -9.7% | +12.0% | −21.7 pts | ||
| 3 years | -32.4% | +78.2% | −110.5 pts | -12.2% | +21.2% |
| 5 years | -85.9% | +73.2% | −159.1 pts | -32.4% | +11.6% |
| 10 years | +87.6% | +309.6% | −222.0 pts | +6.5% | +15.1% |
Ten years at a glance
Fiscal years 2016 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases InMode filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About InMode
Electromedical & Electrotherapeutic Apparatus
InMode Ltd. designs, manufactures, and commercializes minimally invasive and non-invasive medical and surgical systems. The company develops energy-based aesthetic treatment platforms, offering equipment, consumables, and related maintenance services. Its product lines encompass multiple branded platforms such as BodyTite, Morpheus8, Optimas, EvolveX, EmpowerRF, Triton, Votiva, Luxora, and ApexRF. These systems serve clinical applications across aesthetic surgery, plastic surgery, dermatology, gynecology, and ophthalmology. InMode provides these products to a diverse base of healthcare professionals, including plastic surgeons, dermatologists, obstetricians and gynecologists, otolaryngologists, ophthalmologists, and aesthetic medical practitioners.
Company profile, executives and historyInMode stock: common questions
What is InMode's stock price?
INMD closed at $13.19 on Nov 12, 2026, down 3.93% on the day. Over the past 52 weeks it traded between $12.72 and $16.67.
What is InMode's market cap?
InMode was worth $835.70M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is INMD's P/E ratio?
INMD trades at 9.2 times earnings, based on diluted earnings per share of $1.43 over fiscal 2025.
How much revenue does InMode make?
InMode reported revenue of $370.50M for fiscal 2025, down 6.2% from a year earlier.
Does InMode pay a dividend?
No. InMode has not paid a cash dividend over the last twelve months.
How has INMD stock performed over the past year?
Including dividends, INMD returned -9.7% over the past year, against +12.0% for the S&P 500.
How many INMD shares are sold short?
2M shares were sold short at the latest FINRA report, 4.08% of the float, or 4.8 days of average trading volume.
Who are InMode's competitors?
Companies most similar to InMode by business, industry and size include AXGN, SKIN, ESTA, TMDX, FOCL.
See a number that looks wrong?